文献速递产科母胎医学

全州范围内传统与基于游离DNA的产前检测路径的使用情况与性能:维多利亚围产期记录链接(PeRL)研究

State-wide utilization and performance of traditional and cell-free DNA-based prenatal testing pathways: the Victorian Perinatal Record Linkage (PeRL) study.
PubMed 文献 · Ultrasound Obstet Gynecol · 2020-01-01

该回顾性研究链接澳大利亚维多利亚州2015年接受cfDNA、早孕期联合筛查(CFTS)、中孕期血清筛查(STSS)及产前产后细胞遗传学检测女性的个体记录,获得人群使用率与筛查性能估计。CFTS对T21、T18、T13合并敏感性89.57%(95%CI 82.64-93.93%),筛查阳性率2.94%;cfDNA合并敏感性100%(95%CI 95.00-100%),筛查阳性率1.21%。低风险筛查后重大染色体异常残余风险CFTS为1/1188,cfDNA为1/762(P=0.13)。

要点

  • 2015年维多利亚州79140例出生中,66166例(83.6%)女性接受了至少一种非整倍体筛查。
  • CFTS对T21、T18、T13合并敏感性89.57%(95%CI 82.64-93.93%),筛查阳性率2.94%。
  • cfDNA对T21、T18、T13合并敏感性100%(95%CI 95.00-100%),筛查阳性率1.21%。

核心结论

  • cfDNA对T21、T18、T13的敏感性明显优于CFTS。
  • 低风险CFTS或cfDNA结果后重大染色体异常残余风险无统计学显著差异,但cfDNA队列中诊断为重大染色体异常的活产儿较少。

研究设计与样本

  • 回顾性研究,纳入2015年居住在澳大利亚维多利亚州并接受产前筛查或侵入性产前诊断的女性。
  • 将多家提供者的患者自费cfDNA转诊数据与全州政府补贴的CFTS、STSS及侵入性诊断操作结果合并。
  • 获取妊娠产物及12月龄以内婴儿的产后细胞遗传学结果,以确认筛查假阴性病例及非典型染色体异常。
  • 使用LinkageWizTM进行个体记录链接。

主要发现

  • 研究期间共有79140例出生,66166例(83.6%)女性接受了至少一种非整倍体筛查。
  • 筛查女性中93.5%(n=61877)链接数据完整,其中73.2%(n=45275)仅接受CFTS,20.2%(n=12486)仅接受cfDNA,5.3%(n=3268)仅接受STSS,1.3%(n=813)同时接受CFTS和cfDNA,<0.1%(n=35)同时接受STSS和cfDNA。
  • CFTS对T21、T18、T13合并敏感性89.57%(95%CI 82.64-93.93%),筛查阳性率2.94%;CFTS路径有12例假阴性,包括10例T21、1例T18和1例T13。
  • cfDNA对T21、T18、T13合并敏感性100%(95%CI 95.00-100%),筛查阳性率1.21%;将任何染色体(包括性染色体)高风险cfDNA结果及cfDNA检测失败视为筛查阳性时,cfDNA筛查阳性率增至2.42%。
  • 低风险筛查结果后产前或产后诊断检测发现任何重大染色体异常(包括非典型异常)的风险:CFTS为1/1188(n=37),cfDNA为1/762(n=16)(P=0.13)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To perform individual record linkage of women undergoing screening with cell-free DNA (cfDNA), combined first-trimester screening (CFTS), second-trimester serum screening (STSS), and/or prenatal and postnatal cytogenetic testing with the aim to (1) obtain population-based estimates of utilization of prenatal screening and invasive diagnosis, (2) analyze the performance of different prenatal screening strategies, and (3) report the residual risk of any major chromosomal abnormality following a low-risk aneuploidy screening result. METHODS: This was a retrospective study of women residing in the state of Victoria, Australia, who underwent prenatal screening or invasive prenatal diagnosis in 2015. Patient-funded cfDNA referrals from multiple providers were merged with state-wide results for government-subsidized CFTS, STSS and invasive diagnostic procedures. Postnatal cytogenetic results from products of conception and infants up to 12 months of age were obtained to ascertain cases of false-negative screening results and atypical chromosomal abnormalities. Individual record linkage was performed using LinkageWizTM . RESULTS: During the study period, there were 79 140 births and 66 166 (83.6%) women underwent at least one form of aneuploidy screening. Linkage data were complete for 93.5% (n = 61 877) of women who underwent screening, and of these, 73.2% (n = 45 275) had CFTS alone, 20.2% (n = 12 486) had cfDNA alone; 5.3% (n = 3268) had STSS alone, 1.3% (n = 813) had both CFTS and cfDNA, and < 0.1% (n = 35) had both STSS and cfDNA. CFTS had a combined sensitivity for trisomies 21 (T21), 18 (T18) and 13 (T13) of 89.57% (95% CI, 82.64-93.93%) for a screen-positive rate (SPR) of 2.94%. There were 12 false-negative results in the CFTS pathway, comprising 10 cases of T21, one of T18 and one of T13. cfDNA had a combined sensitivity for T21, T18 and T13 of 100% (95% CI, 95.00-100%) for a SPR of 1.21%. When high-risk cfDNA results for any chromosome (including the sex chromosomes) and failed cfDNA tests were treated as screen positives, the SPR for cfDNA increased to 2.42%. The risk of any major chromosomal abnormality (including atypical abnormalities) detected on prenatal or postnatal diagnostic testing after a low-risk screening result was 1 in 1188 for CFTS (n = 37) and 1 in 762 for cfDNA (n = 16) (P = 0.13). The range of chromosomal abnormalities detected after a low-risk cfDNA result included pathogenic copy-number variants (n = 6), triploidy (n = 3), rare autosomal trisomies (n = 3) and monosomy X (n = 2). CONCLUSIONS: Our state-wide record-linkage analysis delineated the utilization and clinical performance of the multitude of prenatal screening pathways available to pregnant women. The sensitivity of cfDNA for T21, T18 and T13 was clearly superior to that of CFTS. While there was no statistically significant difference in the residual risk of any major chromosomal abnormality after a low-risk CFTS or cfDNA result, there were fewer live infants diagnosed with a major chromosomal abnormality in the cfDNA cohort. These data provide valuable population-based evidence to inform practice recommendations and health policies. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Lindquist A, Hui L, Poulton A, et al. State-wide utilization and performance of traditional and cell-free DNA-based prenatal testing pathways: the Victorian Perinatal Record Linkage (PeRL) study. Ultrasound Obstet Gynecol. 2020. PMID: 31625225. doi:10.1002/uog.21899

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。